$Short-term efficacy of angiotensin receptor-neprilysin inhibitor treatment in patients with ST-segment elevation myocardial infarction with reduced ejection fraction after primary percutaneous coronary intervention: a propensity score matching study$

Short-term efficacy of angiotensin receptor-neprilysin inhibitor treatment in patients with ST-segment elevation myocardial infarction with reduced ejection fraction after primary percutaneous coronary intervention: a propensity score matching study

Abstract Background Acute myocardial infarction (AMI) causes a series of pathophysiological changes, including myocardial necrosis, myocardial edema, and microvascular damage. These changes eventually lead to severe cardiovascular events, such as ventricular remodeling, heart failure, and papillary...

Full description

Bibliographic Details
Main Authors:	Qun Zhang, Bao Qiao, Yu Han, Shukun Sun, Bailu Wang, Shujian Wei
Format:	Article
Language:	English
Published:	BMC 2022-11-01
Series:	BMC Cardiovascular Disorders
Subjects:	Ventricular remodeling ST-segment elevation myocardial infarction Angiotensin receptor-neprilysin inhibitor Angiotensin-converting enzyme inhibitor Primary percutaneous coronary intervention
Online Access:	https://doi.org/10.1186/s12872-022-02906-0

Similar Items

Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
by: Tomoko Kato, et al.
Published: (2023-09-01)

Long-Term Effects of Angiotensin Receptor–Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction
by: Gregor Poglajen, et al.
Published: (2020-07-01)

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
by: Hong-Mi Choi, et al.
Published: (2020-05-01)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
by: Kawa Dizaye, et al.
Published: (2019-05-01)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
by: A.S. Ryazanov, et al.
Published: (2023-04-01)

Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
by: Su Yeong Park, et al.
Published: (2023-09-01)

Serum neprilysin levels are associated with myocardial stunning after ST-elevation myocardial infarction
by: Damien Legallois, et al.
Published: (2020-07-01)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
by: Jahanzeb Malik, et al.
Published: (2021-09-01)

Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats
by: Shao-Jung Hsu, et al.
Published: (2020-04-01)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
by: Nathalie Esser, et al.
Published: (2022-06-01)

Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe
by: Donna S.‐H. Lin, et al.
Published: (2021-03-01)

Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor
by: Teng Y, et al.
Published: (2023-08-01)

Anti-hypertensive effect of a novel angiotensin II receptor neprilysin inhibitor (ARNi) -S086 in DSS rat model
by: Jingchao Sun, et al.
Published: (2024-02-01)

Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis
by: Wipharak Rattanavipanon, et al.
Published: (2021-07-01)

Angiotensin receptor‐neprilysin inhibitor in symptomatic patients with Duchenne dilated cardiomyopathy: A primetime
by: Alessandra Arcudi, et al.
Published: (2022-10-01)

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure
by: Frederik H. Verbrugge, et al.
Published: (2020-07-01)

Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion
by: Kangbo Li, et al.
Published: (2023-02-01)

Safety and effectiveness of angiotensin receptor-neprilysin inhibitors in Indian patients with heart failure with preserved ejection fraction – “ARNI-PRESERVED” study
by: Pankaj Jariwala, et al.
Published: (2021-01-01)

Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP‐HF
by: Brittany Chapman, et al.
Published: (2022-06-01)

Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series
by: Sepideh Taghavi, et al.
Published: (2020-12-01)

Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial
by: Julie Hempel Larsen, et al.
Published: (2023-02-01)

Updates for Cardio‐Kidney Protective Effects by Angiotensin Receptor‐Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection
by: Shunichiro Tsukamoto, et al.
Published: (2023-04-01)

B-Type Natriuretic Peptide (BNP) Revisited—Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?
by: Toshio Nishikimi, et al.
Published: (2022-07-01)

Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction
by: Akihiro Nakamura, et al.
Published: (2023-01-01)

Application of Angiotensin Receptor–Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus
by: Liangying Gan, et al.
Published: (2022-07-01)

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis
by: Pankaj Jariwala, et al.
Published: (2021-03-01)

Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
by: M. O.E. Irhuma, et al.
Published: (2016-11-01)

Protective effect of novel angiotensin receptor neprilysin inhibitor S086 on target organ injury in spontaneously hypertensive rats
by: Ying Xiao, et al.
Published: (2024-01-01)

The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation
by: A. S. Ryazanov, et al.
Published: (2023-01-01)

Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension
by: Wanjing Li, et al.
Published: (2022-04-01)

Reply to Siniorakis et al., “COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure”
by: David S. Fedson, et al.
Published: (2020-06-01)

Critical angioedema induced by a renin angiotensin system blocker in the contemporary era of increasing heart failure: A case report and commentary
by: Masafumi Sato, et al.
Published: (2021-03-01)

Long‐term impact of angiotensin receptor‐neprilysin inhibitor based on short‐term treatment response in heart failure
by: Hyuk Kyoon Park, et al.
Published: (2023-12-01)

Effects of the Angiotensin‐Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta‐Analysis
by: Yiwen Wang, et al.
Published: (2019-07-01)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
by: Henry Sutanto, et al.
Published: (2021-08-01)

Initiation, treatment response evaluation, and safety monitoring of angiotensin receptor/neprilysin inhibitors (Sacubitril/Valsartan) in the management of heart failure in India: An expert group recommendations
by: Uday M Jadhav, et al.
Published: (2023-01-01)

Effects of angiotensin receptor‐neprilysin inhibitor on insulin resistance in patients with heart failure
by: Yusuke Kashiwagi, et al.
Published: (2023-06-01)

Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Angiotensin Receptor‐Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real‐World Data
by: Alvaro Alonso, et al.
Published: (2024-03-01)

Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure
by: Sheldon E. Litwin, et al.
Published: (2022-12-01)

The Application of Angiotensin Receptor Neprilysin Inhibitor in Cardiovascular Diseases: A Bibliometric Review From 2000 to 2022
by: Xia Xu, et al.
Published: (2022-05-01)